80results about How to "Prevention and reduction of severity" patented technology

Therapeutic methods for enhancing neurologic function such as may be desired in individuals having motor and / or cognitive impairment, including that resulting from Alzheimer's disease, dementia, head trauma, mental disease such as depression, stroke and neurodegeneration, as well as in healthy individuals are described, the methods including delivering a cognitive enhancing effective amount of light energy having a wavelength in the visible to near-infrared wavelength range to a target area of the brain. The neurologic function enhancing effective amount of light energy, in accordance with a preferred embodiment, is a predetermined power density (mW / cm2) at the level of the brain tissue being treated, and is delivered by determining a surface power density of the light energy that is sufficient to deliver the predetermined power density of light energy to the target brain tissue. In one embodiment, progenitor cells are treated using light energy and implanted into the central nervous system of a patient.

Immunogenic polysaccharide-protein conjugates having a polysaccharide antigen (or its oligosaccharide fragment representing one or more antigenic epitopes) derived from a nosocomial pathogen conjugated to a staphylococcal surface adhesin carrier protein are used in immunogenic compositions to elicit antibody responses to both the polysaccharide antigen and the staphylococcal surface adhesin carrier protein. Such immunogenic compositions are used to immunize against diseases caused by Staphylococcal aureus, Staphylococcal epidermidis or other nosocomial pathogens.

The invention provides a micro-control neuroprosthetic device and methods for predicting and controlling epileptic neuronal activity. The device includes a detection system that detects and collects electrophysiological information comprising action potentials from single neurons and ensembles of neurons in a neural structure such as an epileptogenic region of the brain in a subject. An analysis system included in the neuroprosthetic device evaluates the electrophysiological information and performs a real-time extraction of neuron firing features from which the system determines when stimulus intervention is required. The neuroprosthetic device further comprises a stimulation intervention system that provides stimulus output signals having a desired stimulation frequency and stimulation intensity directly to the neural structure in which abnormal neuronal activity is detected. The analysis system further analyzes collected electrophysiological information during or following stimulus intervention to assess the effects of the stimulation intervention and to provide outputs to maintain or modify the stimulation intervention.

Methods and devices are described for electrically stimulating nerves and organs to induce and modulate the production of hormones according to desired hormone production patterns and hormone level patterns to treat gynecological conditions. Such methods and devices may be used to treat or alleviate the symptoms of menopause. In addition, such methods and devices may be used for birth control.

Pannus-resisting implantable medical devices comprise one or more antimicrobial reservoirs, each such reservoir incorporating antimicrobial substances in predetermined distributions for timed release in vivo. Predetermined distributions of antimicrobial substances incorporated in antimicrobial reservoirs are achieved through use of fluid solvent carriers, which may comprise supercritical fluid solvents. Precipitation of antimicrobial substances from such solvent carriers in predetermined distributions is accomplished through evaporation and / or application of heating, cooling or decreased ambient pressure to the solvent carriers.

Immunogenic polysaccharide-protein conjugates having a polysaccharide antigen (or its oligosaccharide fragment representing one or more antigenic epitopes) derived from a nosocomial pathogen conjugated to a staphylococcal surface adhesin carrier protein are used in immunogenic compositions to elicit antibody responses to both the polysaccharide antigen and the staphylococcal surface adhesion carrier protein. Such immunogenic compositions are used to immunize against diseases caused by Staphylococcal aureus, Staphylococcal epidermidis or other nosocomial pathogens.

Methods and devices for electrically stimulating nerves and organs to induce and modulate the production of hormones according to desired hormone production patterns and hormone level patterns to treat gynecological conditions. Such methods and devices may be used to treat or alleviate the symptoms of menopause. In addition, such methods and devices may be used for birth control.

The present invention features methods of delivering corticosteroids or metabolites thereof for treating and preventing tissue damage resulting from acute radiation injury in the gastrointestinal tract with locally effective therapeutic agents.

The present invention provides a method of providing acute neuroprotection by inducing the erythropoietin (EPO) signaling pathway in neuronal cells close to or subsequent to the time of excitatory insult; and inducing an insulin-like growth factor (IGF) signaling pathway in the neuronal cells close to or subsequent to the time of excitatory insult, thereby producing a synergistic acute neuroprotective effect in the neuronal cells. The invention also provides a method of preventing or reducing the severity of a neurologic condition in a subject by administering to the subject EPO or an active fragment or analog thereof at a dose of at most 2000 U / kg; and administering to the subject an IGF or an active fragment or analog thereof, thereby providing neuroprotection and preventing or reducing the severity of the neurologic condition. Such a method can be used to prevent or reduce the severity of, for example, Alzheimer's disease, Parkinson's disease, Huntington's disease, epilepsy, amyotrophic lateral sclerosis, multiple sclerosis, a movement disorder, HIV-associated dementia, HIV-associated neuropathy, neuropathic pain, migraine, glaucoma, drug addiction, drug withdrawal, drug dependency, depression or anxiety.

Disclosed are antibodies that bind to the stem region of influenza hemagglutinin in the neutral pH conformation, hemagglutinin epitopes in the stem region, and methods of making and using both.

The present invention provides a method of providing acute neuroprotection by inducing the erythropoietin (EPO) signaling pathway in neuronal cells close to or subsequent to the time of excitatory insult; and inducing an insulin-like growth factor (IGF) signaling pathway in the neuronal cells close to or subsequent to the time of excitatory insult, thereby producing a synergistic acute neuroprotective effect in the neuronal cells. The invention also provides a method of preventing or reducing the severity of a neurologic condition in a subject by administering to the subject EPO or an active fragment or analog thereof at a dose of at most 2000 U / kg; and administering to the subject an IGF or an active fragment or analog thereof, thereby providing neuroprotection and preventing or reducing the severity of the neurologic condition. Such a method can be used to prevent or reduce the severity of, for example, Alzheimer's disease, Parkinson's disease, Huntington's disease, epilepsy, amyotrophic lateral sclerosis, multiple sclerosis, a movement disorder, HIV-associated dementia, HIV-associated neuropathy, neuropathic pain, migraine, glaucoma, drug addiction, drug withdrawal, drug dependency, depression or anxiety.

In certain aspects, the present invention provides compositions and methods for treating mucositis.

In certain aspects, the present invention provides compositions and methods for treating mucositis.

The present invention relates to biphenyl-pyrazole compounds and in particular biphenyl-pyrazolecarboxamides. The invention further provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by antagonism or inverse agonism of the CB1 receptor, such as obesity, smoking cessation, and normalization of blood lipid composition.

Oxazole derivatives, which are useful as VEGFR2, CDK2, and CDK4 inhibitors are described herein. The described invention also includes methods of making such oxazole derivatives as well as methods of using the same in the treatment of hyperproliferative diseases.

The present invention relates to biphenyl-pyrazole compounds and in particular biphenyl-pyrazolecarboxamides. The invention further provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by antagonism or inverse agonism of the CB1 receptor, such as obesity, smoking cessation, and normalization of blood lipid composition.

Methods and compositions containing huperzine are used to prevent and alleviate neuropathic pain. The invention is also directed to methods and compositions for using huperzine for the prevention and / or treatment of neuropathic pain and orthostatic hypotension.

Methods and compositions containing huperzine are used to alleviate pain and for the prevention and / or treatment of seizures and epilepsy. The invention is also directed to methods and compositions for using huperzine for the prevention and / or treatment of neuropathic pain and orthostatic hypotension.

The invention relates to compositions comprising a CD4 lymphocyte depleting agent; and methods of using the compositions to treat, prevent, reduce the severity of and / or slow the progression of a condition in a subject. The invention also relates to use of combinations of a CD4 lymphocyte depleting agent and at least one additional agent to treat, prevent, reduce the severity of and / or slow the progression of a condition in a subject. The additional agent may be an immune check point inhibitor, an adoptive immune therapeutic, an immune adjuvant, or an immune modulating agent, or their combinations.

The present invention provides a method of providing acute neuroprotection by inducing the erythropoietin (EPO) signaling pathway in neuronal cells close to or subsequent to the time of excitatory insult; and inducing an insulin-like growth factor (IGF) signaling pathway in the neuronal cells close to or subsequent to the time of excitatory insult, thereby producing a synergistic acute neuroprotective effect in the neuronal cells. The invention also provides a method of preventing or reducing the severity of a neurologic condition in a subject by administering to the subject EPO or an active fragment or analog thereof at a dose of at most 2000 U / kg; and administering to the subject an IGF or an active fragment or analog thereof, thereby providing neuroprotection and preventing or reducing the severity of the neurologic condition. Such a method can be used to prevent or reduce the severity of, for example, Alzheimer's disease, Parkinson's disease, Huntington's disease, epilepsy, amyotrophic lateral sclerosis, multiple sclerosis, a movement disorder, HIV-associated dementia, HIV-associated neuropathy, neuropathic pain, migraine, glaucoma, drug addiction, drug withdrawal, drug dependency, depression or anxiety.

The present disclosure provides methods for treating allergy comprising selecting a patient with an allergy and administering a therapeutically effective amount of an IL-4 / IL-13 pathway inhibitor (e.g., an anti-IL-4 receptor antibody or antigen-binding fragment thereof) in combination with a therapeutically effective amount of an agent that depletes plasma cells (e.g., an anti-BCMA / anti-CD3 bispecific antibody). In certain embodiments, a plasma cell ablating agent such as an anti-BCMA / anti-CD3 bispecific antibody ablates the plasma cells, including IgE+ plasma cells, while the IL-4 / IL-13 pathway inhibitor prevents the generation of new IgE+ plasma cells, thus eliminating allergen-specific IgE in the patient.

The present invention is directed towards a lyophilized or reconstituted multi-antigen or multicomponent immunogenic composition comprising at least one antigen isolated from a staphylococcal bacterium, and methods of making the same.

The present invention relates to compositions and methods for treating of cancer. In some embodiments, the invention relates to the use of agents that can modulate a component in the CDX2-KLF4 signaling pathway to treat myelodysplastic syndromes (MDS), acute myelogenous leukemia (AML), acute lymphocytic leukemia (ALL), adult T-cell leukaemia (ATLL), lymphoma, gastric cancer, multiple myeloma, or combinations thereof, or a condition associated with abnormal activity of the CDX2-KLF4 signaling pathway.

Methods and compositions containing huperzine for direct delivery to central nervous system (CNS) tissue are used to alleviate pain and for the prevention and / or treatment of seizures and epilepsy. The invention is also directed to methods and compositions for using huperzine for the prevention and / or treatment of neuropathic pain and orthostatic hypotension.